

5 and

6 b) administering to the mammal a therapeutically effective amount of a
7 TRANCE agonist pharmaceutical composition of Claim 27.

1 30 The method for treating an immune system related condition as set forth in
2 Claim 29, wherein said antigen is selected from the group consisting of:
3 a) a pathogen, or a fragment thereof;
4 b) a virus, or a fragment thereof; and
5 c) a tumor, or a fragment thereof.

1 31. The method for treating an immune system related condition as set forth in
2 Claim 29, wherein the immune system related condition is HIV or cancer.

1 32. The method for treating an immune system related condition as set forth in
2 Claim 29, wherein said pharmaceutically composition is administered orally,
3 pulmonarily, or nasally.

1 33. The method for treating an immune system related condition as set forth in
2 Claim 29, further comprising the steps of removing the at least one mature
3 dendritic cell from the mammal prior to the exposing step, and
4 reintroducing the mature dendritic cell into the mammal after the exposing
5 step, and prior to the administering step.

1 34. The method for treating an immune system related condition as set forth in
2 Claim 33, wherein the antigen is selected from the group consisting of:
3 a) a pathogen, or a fragment thereof;
4 b) a virus, or a fragment thereof; and
5 c) a tumor, or a fragment thereof.

1 35. The method for treating an immune system related condition as set forth in
2 Claim 33, wherein the immune system related condition is HIV or cancer.